Background: Lymph node (LN) counts from pancreatectomy are postulated as quality metric for
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Background
Pancreatic cancer and other periampullary cancers remain formidable health care challenges for which few effective therapeutic options exist. For apparently localized tumors, resection continues to provide some important benefit, albeit rarely curative 1 . Complexity of pancreatectomy and a high morbidity potential call for appropriate specialty expertise when performing such operations. Adhering to high technical and oncological resection standards, among other important selection and care parameters, has become a critical mandate to deliver appropriate care and achieve best possible outcomes such as obtaining low rates of margin positivity, minimizing locoregional recurrence and prolonging survival. Although efforts to extend the regional dissection during pancreatectomy for cancer have failed to show measurable survival benefits in several randomized controlled trials [2] [3] [4] [5] , total lymph node (LN) counts after pancreatic resections nevertheless are linked to staging accuracy and may impact regional disease control 6 . Conclusive data that support a causative impact of increased lymph node removal on improved pancreatic cancer survival outcomes are lacking. A minimum total LN count of 12 is recommended for pathologic staging of pancreatic cancer 7 , although this requirement is not only not often met throughout the U.S. but missed in the majority of cases, based on population data [8] [9] [10] [11] . Meeting this expectation or exceeding it has been discussed as one possible aspect representing the quality of operative dissection and histopathologic analysis of pancreatectomy specimens, analogous to currently accepted guidelines for regional lymphatic dissection of colorectal cancers 11 ; nevertheless, controlling for operative versus pathologic influences on LN counts has been challenging for the concept of accepting LN counts as quality metric. This
analysis of a surgical experience with a consistent operative approach seeks to study institutional variability among LN counts and related parameters after pancreatectomy.
Patients and Methods
The analysis is based on prospectively collected data from a single surgeon's consecutive pancreatectomy experience within four different institutions. These included a nonacademic tertiary cancer center (Institution A), a university HPB practice (B), an academic cancer center with better survival, independent of stage-specific survival 8, 9 . It is acknowledged, however, that higher LN counts may also be a surrogate for other variables such as greater administration of chemotherapy 11 . Several randomized trials of extended LN dissection during pancreatectomy for cancer have failed to show convincing support for any survival benefit. Extending the regional dissection beyond a standard dissection has likely failed in this setting because the "standard" dissection already included reasonable LN groups for dissection and acceptable counts beyond which further lymphadenectomy is less likely to mediate further measurable benefit [3] [4] [5] .
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Should a minimum number of LNs examined thus be recommended for pancreas cancer resections? It is clear that throughout the US population, the minimum staging recommendation of 12 LNs is missed in the majority of cases [8] [9] [10] . The results show that pancreatectomy-associated LN counts varied considerably between institutions. While the recommended staging requirements were met or exceeded in between 80
to 98% of cases in three institutions, this was the case in just around half of cases in the fourth institution. Reasons will likely originate in gross pathologic specimen preparation and examination standards, but certainly could reflect other differences between institutions in patient overall health, nutrition status, therapeutic aspects etc. Reliable data that LN counts after pancreatectomy vary between institutions do not exist; however, examples from other disease types such as endometrial or colon cancers suggest that this is indeed the case 12, 13 . In addition, interobserver and intraobserver variability among pathologists is a well-documented phenomenon 14 . Although is is methodologically challenging to define the impact of surgeon, pathologist, patient and institution on variations in the resulting LN count, it has been suggested M A N U S C R I P T
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9 that for resected colon cancer, surgeon and pathologist impact was observed to be smaller than those of institution and patient variability 13 .
Should pathologists invest effort in finding additional LNs once a positive LN has been identified? While for pancreatic cancer this may be an appropriate question, for other nonpancreatic periampullary cancers with generally more moderate survival hazards this will be less debatable. For all these epithelial cancers, number of positive LNs as well as number of negative LNs (or total LN counts) have shown significant overall survival impact at least in large population database or multi-institutional trial analyses 6, 8 . Consequently, defining appropriate LN numbers seems to be a reasonable pathologic objective, if at a minimum to meet proper staging objectives. How relevant may LN counts be for benign conditions leading to resection? It should be noted that in the current series, in a considerable number of resections the definitive malignant or benign nature of the underlying process was not known at the time of the procedure, as for most neuroendocrine or mucinous cystic neoplasms, and that the resulting resection extent included regional dissection with splenic vascular resection in case a malignant process was to be identified. Interestingly, the institution with the lowest average LN counts for cancerous lesions also was found to have the lowest LN numbers reported for benign conditions.
It appears noteworthy that the consistently highest counts in the current series were obtained in the community practice environment. Perhaps the proximity between surgeon and pathologist and the lack of potential challenges in a pathology laboratory training environment can lead to persistently diligent results. Along this notion, differences in LN counts for benign diagnoses may also result from a varying degree of importance lent to LN analysis in nonmalignant disease.
The data also support an association between LN counts and nodal positivity, i.e. a greater sensitivity for staging and the potential for some stage migration with increasing LN counts up to M A N U S C R I P T A C C E P T E D 
